We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics - An LGC Company

Download Mobile App




Diagnostic Test Identifies Resistance Mutation that Enables Use of Inexpensive, Single Dose Gonorrhea Drug

By LabMedica International staff writers
Posted on 17 Aug 2020
Print article
This photomicrograph of a Gram-stained urethral smear specimen, reveals some of the histopathology in an acute case of gonococcal urethritis, caused by the Gram-negative bacterium, Neisseria gonorrhoeae.  (Image courtesy of [U.S.] Centers for Disease Control and Prevention\'s Public Health Image Library)
This photomicrograph of a Gram-stained urethral smear specimen, reveals some of the histopathology in an acute case of gonococcal urethritis, caused by the Gram-negative bacterium, Neisseria gonorrhoeae. (Image courtesy of [U.S.] Centers for Disease Control and Prevention\'s Public Health Image Library)
By detecting the mutated gene responsible for resistance to the drug ciprofloxacin, it is possible to identify gonorrhea patients who can be cured by a single oral dose of this drug.

Gonorrhea, a sexually transmitted infection (STI) caused by Neisseria gonorrhoeae, remains a major public health issue worldwide with the World Health Organization (WHO) estimating that 87 million new cases of gonorrhea occur annually. Untreated gonorrhea contributes to serious reproductive and sexual health problems, including pelvic inflammatory disease, infertility, and an increased risk of transmission of human immunodeficiency virus (HIV).

Use of the inexpensive oral antibiotic ciprofloxacin to treat gonorrhea has largely been discontinued over concerns that the bacterium was becoming resistant to it. On the other hand, a molecular assay that predicts in vitro ciprofloxacin susceptibility is now available but has not been systematically studied in human infections.

Investigators at the University of California, Los Angeles (USA) used this genotypic polymerase chain reaction assay to determine the status of the N. gonorrhoeae gyrase subunit A serine 91 codon. They then conducted a multisite prospective clinical study of the efficacy of a single oral dose of ciprofloxacin 500 mg in patients with culture-positive gonorrhea. Follow-up specimens for culture were collected to determine microbiological cure five to 10 days post-treatment.

Results showed that of the 106 subjects possessing culture-positive infections with wild-type gyrA serine N. gonorrhoeae genotype, the efficacy of single-dose oral ciprofloxacin treatment was 100%. Thus, oral ciprofloxacin was highly effective against infections caused by the bacterium lacking the gyrA serine mutation.

"The new test gives doctors more choices to treat the sexually transmitted infection and could help slow down the spread of drug-resistant gonorrhea," said first author Dr. Jeffrey Klausner, professor of medicine at the University of California, Los Angeles. "Gonorrhea is one of the most common drug-resistant infections worldwide and is becoming harder to treat. Current treatment methods require an antibiotic injection, which is expensive and painful. This new test could make it easier and safer to treat gonorrhea with different antibiotics, including one pill given by mouth. Using a pill instead of a shot would also make it easier and faster to treat sex partners of patients with gonorrhea."

The paper was published in the August 7, 2020, online edition of the journal Clinical Infectious Diseases.

Related Links:

University of California, Los Angeles

Gold Supplier
Auto Urinary Sediment Analyzer
EH-2030
New
Dual-Channel Optical Coagulation Analyzer
Sensa2
New
Cytomegalovirus ELISA Test
Captia Cytomegalovirus (CMV) IgM EIA
New
TSI Stimulating Assay
Thyretain TSI Stimulating Reporter BioAssay

Print article
IIR Middle East

Channels

Molecular Diagnostics

view channel
Image: Mindray ToRCH reagents deliver excellent seroconversion sensitivity (Photo courtesy of Mindray)

Mindray Launches High-Sensitivity and High-Specificity ToRCH Panel

Mindray (Shenzhen, China) has launched the ToRCH Panel that provides high-quality assays to meet different clinical needs. Thanks to the improved raw materials, processes, formulas, reaction models, and... Read more

Technology

view channel
Image: OneDraw Blood Collection Device significantly reduces obstacles for drawing blood (Photo courtesy of Drawbridge Health)

Near Pain-Free Blood Collection Technology Enables High-Quality Testing

Blood tests help doctors diagnose diseases and conditions such as cancer, diabetes, anemia, and coronary heart disease, as well as evaluate organ functionality. They can also be used to identify disease... Read more

Industry

view channel
Image: The global infectious disease IVD market is expected to hit USD 57 billion by 2030 (Photo courtesy of Pexels)

Global Infectious Disease IVD Market Dominated by Molecular Diagnostics Technology

The global infectious disease in vitro diagnostics (IVD) market stood at USD 113.7 billion in 2021 and is expected to grow at a CAGR of -7.41% from 2022 to 2030 to hit around USD 56.89 billion by 2030,... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.